Iovance reports record Q2 revenue ~$99M (+66% YoY); reviewing FY26 guidance; FDA FTD for lifileucel in sarcomas

IOVANCE BIOTHERAPEUTICS, INC.

Total product revenue ~$99M, up 66% from ~$60M in Q2 2025 and 39% from ~$71M in Q1 2026.
U.S. Amtagvi revenue ~$91M, up 40% from Q4 2025; gross margin improved to 56%.
Cash position ~$304M as of June 30, 2026, expected to fund operations into 2H28.
FDA granted Fast Track Designation for lifileucel in soft tissue sarcomas (UPS/DDLPS); SARATOGA trial ORR 50% in first six patients.
Australia TGA approved Amtagvi MAA; UK MAA resubmitted for expedited review; FY26 revenue guidance of $350-370M under review.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.